SAM
NTLA icon

Shell Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Shell Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$27K Sell
1,563
-44,888
-97% -$553K ﹤0.01% 996
2025
Q2 		$436K Buy
46,451
+17,685
+61% +$145K 0.02% 526
2025
Q1 		$205K Sell
28,766
-1,209
-4% -$12.2K 0.01% 787
2024
Q4 		$350K Buy
29,975
+9,403
+46% +$147K 0.02% 615
2024
Q3 		$423K Buy
+20,572
New +$474K 0.02% 550
2024
Q1 		$459K Sell
20,521
-2,280
-10% -$63.3K 0.02% 501
2023
Q4 		$695K Sell
22,801
-1,620
-7% -$46.6K 0.03% 408
2023
Q3 		$772K Sell
24,421
-55
-0.2% -$2.13K 0.03% 415
2023
Q2 		$998K Buy
24,476
+22,784
+1,347% +$924K 0.04% 362
2023
Q1 		$63K Sell
1,692
-6
-0.4% -$235 ﹤0.01% 1164
2022
Q4 		$59K Sell
1,698
-344
-17% -$16.4K ﹤0.01% 1246
2022
Q3 		$114K Sell
2,042
-534
-21% -$33.1K ﹤0.01% 1184
2022
Q2 		$133K Buy
2,576
+4
+0.2% +$203 ﹤0.01% 1218
2022
Q1 		$187K Sell
2,572
-380
-13% -$32.2K ﹤0.01% 1176
2021
Q4 		$349K Buy
2,952
+17
+0.6% +$2.13K 0.01% 1057
2021
Q3 		$394K Buy
+2,935
New +$444K 0.01% 972

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Shell Asset Management's NTLA Position: Q3 2025 in Review

Shell Asset Management reduced its Intellia Therapeutics (NTLA) stake by 97% in Q3 2025, selling an estimated $553K and leaving 1,563 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #996.

Shell Asset Management first reported a position in NTLA in Q3 2021 and has held it in 16 quarters since. The position peaked at $998K in Q2 2023. 283 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

  • Shell Asset Management held 1,563 shares of Intellia Therapeutics worth $27K as of Q3 2025.
  • Shell Asset Management sold 44,888 Intellia Therapeutics shares in Q3 2025, an estimated $553K.
  • Intellia Therapeutics made up ﹤0.01% of Shell Asset Management's portfolio in Q3 2025, its #996 holding.
  • Shell Asset Management first reported a position in Intellia Therapeutics in Q3 2021 and has held it in 16 quarters since.
  • Shell Asset Management's Intellia Therapeutics position peaked at $998K in Q2 2023.
  • 283 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.